Clinical trial · Observational
Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC
Clinical Study of Dynamic Contrast-enhanced Magnetic Resonance Imaging Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver Metastasis of Breast Cance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to further use DCE-MRI and ivim-dwi to predict the chemotherapy sensitivity of liver metastasis of breast cancer at an early stage, and to predict the treatment response of tumor at an early stage by using the changes of their functional parameters, and to compare the efficacy and advantages of IVIM functional parameters and DCE-MRI parameters in predicting the efficacy.To explore the efficacy of "perfusion" and "diffusion" parameters of magnetic resonance imaging as "biomarkers" for early prediction of chemotherapy response and prognosis of breast cancer patients with liver metastasis. And to provide guidance for optimizing the clinical treatment scheme of breast cancer patients with liver metastasis. At the same time, this study will use the method of artificial intelligence to deeply mine the images, and further find out the indicators for early prediction of the therapeutic effect of liver metastasis of breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer in the Liver | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Patients with liver metastasis from breast cancer requiring antitumor therapy
- description
- Patients with liver metastasis from breast cancer requiring antitumor therapy
- interventionNames
- Drug: Chemotherapy
Primary outcomes (2)
- measure
- Correlation between DCE-MRI parameters combined with IVIM parameters and short-term efficacy of chemotherapy in patients with liver metastasis of breast cancer
- timeFrame
- September 2025
- description
- Correlation between DCE-MRI parameters (Ktrans, Ve, Kep) combined with IVIM parameters (D\*, D, f) and short-term efficacy of chemotherapy in patients with liver metastasis of breast cancer
- measure
- Correlation between DCE-MRI parameters combined with IVIM parameters and long-term efficacy of chemotherapy in patients with liver metastasis of breast cancer
- timeFrame
- September 2025
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. The primary lesion was pathologically confirmed to be breast cancer, and the patients diagnosed by two imaging methods or pathologically confirmed to be liver metastasis of breast cancer had at least one liver metastasis with the longest diameter ≥ 10mm; 2. No second primary malignant tumor; 3. ECOG score, 0-2 ; 4. The organ function is normal and can tolerate chemotherapy and other anti-tumor treatments; 5. The patient plans to receive systemic chemotherapy or systemic anti-tumor treatment, and the whole process of cooperative treatment. The patient has good compliance with the planned treatment and follow-up, can understand the research process of this study and sign a written informed consent; 6. Contraception during the study period and within 6 months after treatment, non lactation period. Exclusion Criteria: 1. For patients contraindicated to MR examination, such as built-in metal instruments and allergy to contrast agents; 2. The patient had diffuse liver metastasis or the number of liver metastatic tumors was more than 5; 3. Patients who cannot complete 2 cycles of chemotherapy or systemic anti-tumor treatment; 4. Unable to cooperate with follow-up; 5. Patients who are not suitable for the study according to the investigator.
References
Publications (18)
- RESULTRuiz A, Sebagh M, Wicherts DA, Castro-Benitez C, van Hillegersberg R, Paule B, Castaing D, Vibert E, Cunha AS, Cherqui D, Morere JF, Adam R. Long-term survival and cure model following liver resection for breast cancer metastases. Breast Cancer Res Treat. 2018 Jul;170(1):89-100. doi: 10.1007/s10549-018-4714-1. Epub 2018 Feb 20. PMID 29464535
- RESULTHolm J, Li J, Darabi H, Eklund M, Eriksson M, Humphreys K, Hall P, Czene K. Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis. J Clin Oncol. 2016 Jan 20;34(3):251-8. doi: 10.1200/JCO.2015.63.0624. Epub 2015 Nov 30. PMID 26628467
- RESULTKennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010 Jul 10;28(20):3271-7. doi: 10.1200/JCO.2009.25.9820. Epub 2010 May 24. PMID 20498394
- RESULTGolse N, Adam R. Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results. Clin Breast Cancer. 2017 Jul;17(4):256-265. doi: 10.1016/j.clbc.2016.12.012. Epub 2017 Jan 9. PMID 28196771
- RESULTVaroquaux A, Rager O, Lovblad KO, Masterson K, Dulguerov P, Ratib O, Becker CD, Becker M. Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):842-52. doi: 10.1007/s00259-013-2351-9. Epub 2013 Feb 22. PMID 23436068
- RESULTKoh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007 Jun;188(6):1622-35. doi: 10.2214/AJR.06.1403. PMID 17515386
- RESULTPieper CC, Willinek WA, Meyer C, Ahmadzadehfar H, Kukuk GM, Sprinkart AM, Block W, Schild HH, Murtz P. Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Prediction of Early Arterial Blood Flow Stasis in Radioembolization of Breast Cancer Liver Metastases. J Vasc Interv Radiol. 2016 Sep;27(9):1320-1328. doi: 10.1016/j.jvir.2016.04.018. Epub 2016 Jul 9.